ATE547114T1 - Flüssige zusammensetzungen von factor vii polypeptiden - Google Patents

Flüssige zusammensetzungen von factor vii polypeptiden

Info

Publication number
ATE547114T1
ATE547114T1 AT04738944T AT04738944T ATE547114T1 AT E547114 T1 ATE547114 T1 AT E547114T1 AT 04738944 T AT04738944 T AT 04738944T AT 04738944 T AT04738944 T AT 04738944T AT E547114 T1 ATE547114 T1 AT E547114T1
Authority
AT
Austria
Prior art keywords
factor vii
liquid compositions
vii polypeptides
iii
ionic strength
Prior art date
Application number
AT04738944T
Other languages
English (en)
Inventor
Birthe Hansen
Michael Jensen
Troels Kornfelt
Original Assignee
Novo Nordisk Healthcare Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36816398&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE547114(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from PCT/DK2004/000181 external-priority patent/WO2004082708A2/en
Application filed by Novo Nordisk Healthcare Ag filed Critical Novo Nordisk Healthcare Ag
Application granted granted Critical
Publication of ATE547114T1 publication Critical patent/ATE547114T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
AT04738944T 2003-06-25 2004-06-24 Flüssige zusammensetzungen von factor vii polypeptiden ATE547114T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DKPA200300959 2003-06-25
US48433403P 2003-07-02 2003-07-02
PCT/DK2004/000181 WO2004082708A2 (en) 2003-03-18 2004-03-18 Liquid, aqueous, pharmaceutical compositions of factor vii polypeptides
PCT/DK2004/000447 WO2004112828A1 (en) 2003-06-25 2004-06-24 Liquid composition of factor vii polypeptides

Publications (1)

Publication Number Publication Date
ATE547114T1 true ATE547114T1 (de) 2012-03-15

Family

ID=36816398

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04738944T ATE547114T1 (de) 2003-06-25 2004-06-24 Flüssige zusammensetzungen von factor vii polypeptiden

Country Status (6)

Country Link
US (2) US20060183683A1 (de)
EP (1) EP1641487B1 (de)
JP (1) JP4658041B2 (de)
AT (1) ATE547114T1 (de)
ES (1) ES2382157T3 (de)
WO (1) WO2004112828A1 (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5306597B2 (ja) * 2003-07-01 2013-10-02 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト 第ｖｉｉ因子ポリペプチドの液体水性薬学的組成物
JP4463814B2 (ja) 2003-08-05 2010-05-19 ノボ ノルディスク アクティーゼルスカブ 新規のインスリン誘導体
AU2012213951B2 (en) * 2005-04-28 2014-10-16 Novo Nordisk Health Care Ag A closed container comprising an activated factor VII polypeptide, processes for the preparation of the same, and a kit and a method for use of the kit
US8703706B2 (en) 2005-04-28 2014-04-22 Novo Nordisk Healthcare Ag Closed container comprising an activated factor VII polypeptide, processes for the preparation of the same, and a kit and a method for use of the kit
EP1888117A1 (de) * 2005-05-25 2008-02-20 Novo Nordisk A/S Stabilisierte polypetidformulierungen
US8097584B2 (en) 2005-05-25 2012-01-17 Novo Nordisk A/S Stabilized formulations of insulin that comprise ethylenediamine
US20090074882A1 (en) 2005-12-28 2009-03-19 Novo Nordisk A/S Insulin compositions and method of making a composition
CN104887620A (zh) * 2007-05-02 2015-09-09 诺沃—诺迪斯克保健股份有限公司 包括芳香族防腐剂和抗氧化剂的高浓度因子vii多肽制剂
WO2008152106A1 (en) 2007-06-13 2008-12-18 Novo Nordisk A/S Pharmaceutical formulation comprising an insulin derivative
NL1034535C2 (nl) 2007-10-17 2009-04-20 Vanderlande Ind Nederland Station voor het vanuit producthouders verzamelen van producten in verzamelhouders.
JP2011520999A (ja) * 2008-05-23 2011-07-21 ノボ ノルディスク ヘルス ケア アーゲー 高濃度の芳香族保存料を有するペグ官能化セリンプロテアーゼの製剤
EP2285401A1 (de) * 2008-05-23 2011-02-23 Novo Nordisk Health Care AG Niederviskose zusammensetzungen mit einem pegylierten protein mit gla-domäne
ES2607003T3 (es) 2008-10-30 2017-03-28 Novo Nordisk A/S Tratamiento de diabetes mellitus utilizando inyecciones de insulina con una frecuencia de inyección inferior a la diaria
CN103282042B (zh) * 2010-09-17 2014-12-10 巴克斯特国际公司 通过具有组氨酸的水性制剂在弱酸性至中性pH稳定的免疫球蛋白
HRP20191793T1 (hr) 2010-10-27 2019-12-27 Novo Nordisk A/S Liječenje dijabetesa melitusa injekcijama inzulina koje se primijenjuje u različitim intervalima injiciranja
US8883979B2 (en) 2012-08-31 2014-11-11 Bayer Healthcare Llc Anti-prolactin receptor antibody formulations
JP2016519127A (ja) 2013-04-30 2016-06-30 ノヴォ ノルディスク アー／エス 新規投与レジメン
US10335464B1 (en) 2018-06-26 2019-07-02 Novo Nordisk A/S Device for titrating basal insulin
JP7518149B2 (ja) 2019-07-12 2024-07-17 ノヴォ ノルディスク アー／エス 高濃度インスリン製剤

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US115590A (en) * 1871-06-06 Lfxlproxeixie
DE2916711A1 (de) * 1979-04-25 1980-11-06 Behringwerke Ag Blutgerinnungsfaktoren und verfahren zu ihrer herstellung
US4956386A (en) * 1980-04-25 1990-09-11 Gist-Brocades N.V. Pharmaceutical compositions and process for their preparation
US4404132A (en) 1980-05-27 1983-09-13 Cutter Laboratories, Inc. Blood coagulation promoting product
CA1182748A (en) 1980-11-21 1985-02-19 Gerard Marx Method for synthesizing procoagulant factor viii activity
US4495278A (en) 1981-04-27 1985-01-22 Baxter Travenol Laboratories, Inc. Process for making novel blood clotting enzyme compositions
GR860984B (en) * 1985-04-17 1986-08-18 Zymogenetics Inc Expression of factor vii and ix activities in mammalian cells
US5180583A (en) 1985-11-26 1993-01-19 Hedner Ulla K E Method for the treatment of bleeding disorders
AU593042B2 (en) 1985-11-26 1990-02-01 Novo Nordisk Health Care Ag Compositions and methods for the treatment of bleeding disorders
US5595886A (en) * 1986-01-27 1997-01-21 Chiron Corporation Protein complexes having Factor VIII:C activity and production thereof
JP2593500B2 (ja) 1986-06-24 1997-03-26 ノルデイスク ゲントフテ エー／エス ▲ｖｉｉｉ▼因子フラグメントの凝固活性複合物の製造方法
JP2824430B2 (ja) 1989-08-02 1998-11-11 財団法人化学及血清療法研究所 血液凝固第▲ｖｉｉ▼因子または活性型血液凝固第▲ｖｉｉ▼因子の調製方法
DE4001451A1 (de) * 1990-01-19 1991-08-01 Octapharma Ag Stabile injizierbare loesungen von faktor viii und faktor ix
US5833982A (en) 1991-02-28 1998-11-10 Zymogenetics, Inc. Modified factor VII
US5788965A (en) 1991-02-28 1998-08-04 Novo Nordisk A/S Modified factor VII
WO1994027631A1 (en) 1993-05-21 1994-12-08 Zymogenetics, Inc. Modified factor vii
WO1992015686A1 (en) 1991-02-28 1992-09-17 Zymogenetics, Inc. Modified factor vii
AU2309692A (en) 1991-07-03 1993-02-11 Cryolife, Inc. Method for stabilization of biomaterials
FR2684999A1 (fr) 1991-12-16 1993-06-18 Aquitaine Dev Transf Sanguine Procede de fabrication d'un concentre de facteur vii active de haute purete essentiellement depourvu des facteurs vitamine k dependants et des facteurs viiic et viiicag.
JP3155797B2 (ja) 1991-12-26 2001-04-16 株式会社日立製作所 過電圧自己保護型半導体装置、及び、それを使用した半導体回路
EP0658168B1 (de) 1992-08-27 2000-11-15 Stichting Sanquin Bloedvoorziening Antikoerper spezifisch fur ein haemostatisches protein; seine verwendung zur isolation von intaktem protein; haemostatische zusammensetzungen ohne proteolytische spaltprodukte des proteins
DK38293D0 (da) 1993-03-31 1993-03-31 Novo Nordisk As Fremstilling af proteiner
SE9301581D0 (sv) 1993-05-07 1993-05-07 Kabi Pharmacia Ab Protein formulation
WO1995003332A1 (en) * 1993-07-23 1995-02-02 Baxter International Inc. Activated human factor viii and method of preparation
US6277828B1 (en) * 1993-08-20 2001-08-21 Syntex (U.S.A.) Inc. Pharmaceutical formulations of nerve growth factor
US5576291A (en) * 1993-09-13 1996-11-19 Baxter International Inc. Activated factor VIII as a therapeutic agent and method of treating factor VIII deficiency
US5590109A (en) * 1993-09-17 1996-12-31 Matsushita Electric Industrial Co. Disc apparatus
IL113010A0 (en) * 1994-03-31 1995-10-31 Pharmacia Ab Pharmaceutical formulation comprising factor VIII or factor ix with an activity of at least 200 IU/ml and an enhancer for improved subcutaneous intramuscular or intradermal administration
US6372716B1 (en) 1994-04-26 2002-04-16 Genetics Institute, Inc. Formulations for factor IX
DE4435520A1 (de) 1994-10-04 1996-04-11 Immuno Ag Verfahren zur Trennung von rekombinantem pro-Faktor IX von rekombinantem Faktor IX
SE9403915D0 (sv) * 1994-11-14 1994-11-14 Annelie Almstedt Process A
US5649959A (en) * 1995-02-10 1997-07-22 Sherwood Medical Company Assembly for sealing a puncture in a vessel
US6255091B1 (en) 1995-04-28 2001-07-03 Axys Pharmaceuticals, Inc. Potentiating metal mediated serine protease inhibitors with cobalt or zinc ions
DE19531637A1 (de) 1995-08-28 1997-03-06 Immuno Ag Pharmazeutische Zusammensetzung zur Behandlung von Blutgerinnungsstörugnen, Verfahren zur Herstellung derselben und deren Verwendung
DE19538715A1 (de) 1995-10-18 1997-04-30 Behringwerke Ag Verfahren zur Reinigung von Faktor VII und aktiviertem Faktor VII
US5993795A (en) * 1995-11-09 1999-11-30 Takemoto Yushi Kabushiki Kaisha Protein composition derived from sesame seed and use thereof
US5925738A (en) * 1995-12-01 1999-07-20 The American National Red Cross Methods of production and use of liquid formulations of plasma proteins
US6320029B1 (en) * 1996-11-29 2001-11-20 The American National Red Cross Methods of production and use of liquid formulations of plasma proteins
US5830852A (en) * 1995-12-19 1998-11-03 Cobra Therapeutics, Ltd. Compositions for insulin-receptor mediated nucleic acid delivery
US5770700A (en) * 1996-01-25 1998-06-23 Genetics Institute, Inc. Liquid factor IX formulations
US5927739A (en) 1996-10-07 1999-07-27 Evling; Jens Dual friction wheelchair hand rim
US5804420A (en) 1997-04-18 1998-09-08 Bayer Corporation Preparation of recombinant Factor VIII in a protein free medium
BR9809292A (pt) * 1997-04-28 2000-07-04 Lilly Co Eli Métodos aperfeiçoados para o processamento de proteìna c ativada
US6310183B1 (en) * 1997-09-10 2001-10-30 Novo Nordisk A/S Coagulation factor VIIa composition
AT409334B (de) 1997-09-19 2002-07-25 Immuno Ag Pharmazeutisches präparat enthaltend vitamin k-abhängige einzelfaktoren
AT408613B (de) 1998-06-17 2002-01-25 Immuno Ag Pharmazeutisches faktor vii-präparat
AU1311800A (en) 1998-10-07 2000-04-26 Sigma-Aldrich Co. Thromboplastin reagents and methods for preparing and using such reagents
DK1820516T3 (da) 1999-02-22 2013-10-28 Univ Connecticut Nye albuminfrie faktor VIII-præparater
US20010031721A1 (en) * 1999-05-05 2001-10-18 Chandra Webb Highly concentrated, lyophilized, and liquid factor IX formulations
EP1194161B1 (de) 1999-07-13 2005-11-23 Biovitrum Ab Zusammensetzungen mit stabilem faktor viii
JP2003507388A (ja) 1999-08-17 2003-02-25 ノボ ノルディスク アクティーゼルスカブ 凍結乾燥したケーキの安定化
US6586574B1 (en) * 1999-08-17 2003-07-01 Nn A/S Stabilization of freeze-dried cake
AU6875900A (en) 1999-09-08 2001-04-10 Chugai Seiyaku Kabushiki Kaisha Protein solution preparation and method of stabilizing the same
DE60138364D1 (de) 2000-02-11 2009-05-28 Bayer Healthcare Llc Gerinnungsfaktor vii oder viia konjugate
EP1280548B1 (de) 2000-05-03 2013-12-11 Novo Nordisk Health Care AG Subkutane Verabreichung des Koagulationsfaktor VII
AU2001254624A1 (en) * 2000-05-03 2001-11-12 Novo-Nordisk A/S Human coagulation factor vii variants
ES2254414T3 (es) 2000-05-10 2006-06-16 Novo Nordisk Health Care Ag Composicion farmaceutica comprendiendo un factor vlla y un inhibidor tfpi.
EP1319067A2 (de) 2000-09-13 2003-06-18 Novo Nordisk A/S Varianten des menschlichen koagulationsfaktors vii
KR100880624B1 (ko) * 2000-10-02 2009-01-30 노보 노르디스크 헬스 케어 악티엔게젤샤프트 비타민 ｋ-의존 단백질의 생산 방법
DE50114021D1 (de) 2001-01-08 2008-07-24 Csl Behring Gmbh Stabilisierte Flüssigzubereitung der den Blutgerinnungsfaktor VII aktivierenden Protease oder ihres Proenzyms
US6825323B2 (en) * 2001-01-10 2004-11-30 The United States Of America As Represented By The Secretary Of The Army Compositions for treatment of hemorrhaging with activated factor VIIa in combination with fibrinogen and methods of using same
GB0117879D0 (en) 2001-07-21 2001-09-12 Common Services Agency Storage of liquid compositions
AU2002351756A1 (en) 2001-12-21 2003-07-15 Novo Nordisk Health Care Ag Liquid composition of factor vii polypeptides
AU2002351755A1 (en) 2001-12-21 2003-07-15 Novo Nordisk A/S Liquid composition of modified factor vii polypeptides
KR20040065278A (ko) 2001-12-21 2004-07-21 노보 노르디스크 에이/에스 변경된 인자 ⅶ 폴리펩티드의 액체 조성물
ES2377959T3 (es) 2002-05-03 2012-04-03 Novo Nordisk Health Care Ag Composiciones sólidas estabilizadas de factor VII modificado
US20040009918A1 (en) 2002-05-03 2004-01-15 Hanne Nedergaard Stabilised solid compositions of modified factor VII
AU2003240438A1 (en) 2002-06-21 2004-01-06 Novo Nordisk A/S Stabilised solid compositions of factor vii polypeptides
US6933808B2 (en) 2002-07-17 2005-08-23 Qing Ma Microelectromechanical apparatus and methods for surface acoustic wave switching
EP1422309A1 (de) 2002-11-22 2004-05-26 Siemens Aktiengesellschaft Verwendung einer Sprühkompaktierungsanlage zur Erzeugung einer Schicht und Schichtsystem hergestellt mittels einer Sprühkompaktierungsanlage und Schichtsystem
AT501088A2 (de) 2002-12-18 2006-06-15 Bio Prod & Bio Eng Ag Stabile therapeutische proteine
US7897734B2 (en) 2003-03-26 2011-03-01 Novo Nordisk Healthcare Ag Method for the production of proteins

Also Published As

Publication number Publication date
EP1641487B1 (de) 2012-02-29
WO2004112828A1 (en) 2004-12-29
US20080227715A1 (en) 2008-09-18
US20060183683A1 (en) 2006-08-17
EP1641487A1 (de) 2006-04-05
JP4658041B2 (ja) 2011-03-23
ES2382157T3 (es) 2012-06-05
US7790852B2 (en) 2010-09-07
JP2007508235A (ja) 2007-04-05

Similar Documents

Publication Publication Date Title
IL162239A0 (en) Liquid composition of factor vii polypeptides
ATE547114T1 (de) Flüssige zusammensetzungen von factor vii polypeptiden
BR0215218A (pt) Composição aquosa lìquida, método para a preparação da mesma, uso de uma composição, e, métodos para a inibição da coagulação do sangue em um indivìduo, e inibição de reações mediadas pelo fator de tecido em um indivìduo
BR9714434A (pt) Formulações de interferon liquidas estáveis
MXPA03002218A (es) Peptidos antimicrobianos y metodos de uso.
BRPI0417721A (pt) kit contendo um medicamento farmacêutico, métodos para preparar uma formulação lìquida de um polipeptìdeo de fator de coagulação sangüìnea e para tratar uma sìndrome responsiva a fator de coagulação, uso de um polipeptìdeo de fator vii, composição, e, métodos para preparar as composições e para tratar uma sìndrome responsiva a fvii
EA200501675A1 (ru) Фармацевтическая композиция, содержащая лактат, и ее применение
WO2005016365A3 (en) Liquid, aqueous pharmaceutical composition of factor vii polypeptides
ATE367429T1 (de) Stabilisierte saure chlorbleichmittelzusammensetzung und verfahren zur anwendung
DE602004023725D1 (de) Muteine von tränen-lipocalin
WO2002099027A3 (en) Solid cleaning composition including stabilized active oxygen component
BR0313970A (pt) Composições pesticidas contendo ácidos dicarboxìlicos
ATE527261T1 (de) 7-aryl-3,9-diazabicycloä3.3.1ünon-6-en-derivate und ihre verwendung als renin-inhibitoren zur behandlung von bluthochdruck, herz-kreislauf- erkrankungen und nierenkrankheiten
FI117284B (fi) Materiaaliyhdistelmä veden puhdistamiseksi ja maaperien puhdistamiseksi
WO2003012050A3 (en) Mitochondrial genome replenishment
BR0207826A (pt) Composições pesticidas contendo ácido oxálico
SE9600796D0 (sv) A method of preparing a liquid mixture
ATE505555T1 (de) Fusionsproteine zur insektenbekämpfung
ATE536886T1 (de) Stabilisierte feste zusammensetzungen von modifizierter faktor vii
DE60239329D1 (de) Verwendung von lanthankarbonat zur prävention von nierensteinleiden
ATE294816T1 (de) Neue, physiologisch aktive peptide und ihre verwendung.
ATE365037T1 (de) Verwendung eines eine oxaliplatinlösung beinhaltenden fläschchens
ATE349920T1 (de) Stark saure metallisierte mischungen anorganischer säuren
WO2003053855A3 (en) Rapid high-throughput screen for detecting biological species in ballast water
ATE235509T1 (de) Peptide zur inhibition von hpv e7 proteinen